Protein engineering

Project Details

The ability to identify the effects of mutations is allowing us to optimise proteins for therapeutic and biotechnological purposes.

Engineering antibodies

Antibodies are becoming increasingly important in therapeutic capacity, due to their ability to bind with high specificity and affinity to an enormous variety of substances. Although many programs have been developed to predict the affinity of a protein-protein interaction, none had been specifically designed for antibodies. Antibodies rely on a unique binding mode, interactions through 6 highly variable loops, which is significantly different from general protein-protein interfaces. We hope to harness these features for modelling an antibody's affinity toward its antigen. Using graph-based signatures we have been able to identify mutations altering an antibodies binding affinity. Furthermore, we have been able to identify antibody escape mutations, which lead to reduced effectiveness of these therapies. We are now further developing this into a validated platform that can be used to guide tomorrow's antibody engineering solutions. Other specific efforts include mapping and optimisation of antigenic epitopes, and optimisation of therapeutic antibodies to minimise aggregation and poor pharmacokinetics.

Engineering biotherapeutics

Many potential biotherapeutics are restricted in their therapeutic potential due to inherent significant limitations- including thermal and in vivo instability, immunogenicity and rapid plasma clearance. We have been overcoming these limitations through directed protein engineering, using the predictions from the mutational analysis platform to identify optimal stabilising  and immune masking mutations, with minimal effect on protein activity. In particular we have been applying this to the optimisation of proteins that could be used as enzyme replacement therapies in rare genetic diseases such as Alkaptonuria and OTC deficiency. We are also trying to modify the binding properties of toxins to improve their therapeutic potential.

Optimising biotechnological processes

Using our mutational analysis pipeline we have been analysing the active sites of important industrial enzymes, such as cellulases in bioethanol production, in order to improve their efficiency, activity, stability and reduce feedback inhibition, major limitations in most biotechnological processes.

Designing peptides and nucleic acids that bind to specific proteins

We are developing novel computational methods for assessing peptide and nucleic acid binding affinity to a protein. This will be used as a basis for the development of a de novo design platform of peptides and nucleic acids to target specific proteins with high affinity and specificity. This has practical applications in the in silico identification of optimal binding motifs and the design of novel therapeutics.

We are also using graph-based signatures to evaluate protein structure, chemistry, interactions and geometry. This will help aid in the identification of problems in structures, but are also being used to build tools to identify active sites, and to identify protein, nucleic acid and small molecule interaction sites, including cryptic pockets.

Researchers

Dr David Ascher, Group Leader
Dr Douglas Pires
Carlos Rodrigues, PhD Student
YooChan Myung, PhD Student
Liviu Copoiu, PhD Student
Willy Cornelissen, Masters Student
Vasishth Sidarala, Masters Student

Collaborators

Professor Sir Tom Blundell, University of Cambridge

Dr Lisa Kaminskas, University of Queensland

Professor Chris Smith, University of Cambridge

Funding

Jack Brockhoff Foundation Grant: “Understanding the Molecular Mechanisms of Complex Mutations”.

Research Opportunities

This research project is available to PhD students to join as part of their thesis.
Please contact the Research Group Leader to discuss your options.

Research Publications

  1. Jubb HC, Higuerueloa AP, Ochoa-MontaƱoa B, Pittb, WR, Ascher DB, Blundell TL.  Arpeggio: a web server for calculating and visualising interatomic interactions in protein structures. Journal of Molecular Biology 2016; In Press.
  2. Pires DEV, Ascher DB.  mCSM-AB: a web server for predicting antibody-antigen affinity changes upon mutation with graph-based signatures. Nucleic Acids Research 2016; 44: W469-473.
  3. Pires DEV, Blundell TL, Ascher DB.  mCSM-lig: quantifying the effects of mutations on protein-ligand affinity in genetic disease and the emergence of drug resistance. Scientific Reports 2016; 6: 29575.
  4. Pires DEV, Chen J, Blundell TL, Ascher DB.  In silico functional dissection of saturation mutagenesis: Interpreting the relationship between phenotypes and changes in protein stability, interactions and activity. Scientific Reports 2016; 6: 19848.
  5. Chan LJ, Ascher DB, Yadav R, Bulitta JB, Landersdorfer CB, Porter CJ, Williams CC, Kaminskas LM. Conjugation of 10 kDa linear PEG onto trastuzumab Fab is sufficient to significantly enhance lymphatic exposure while preserving in vitro biological activity. Molecular Pharmaceutics 2016; 13(4): 1229-1241.

Research Group

Ascher laboratory: Structural biology and bioinformatics



Faculty Research Themes

Infection and Immunology, Cancer

School Research Themes

Cancer in Biomedicine, Infection & Immunity, Therapeutics & Translation, Cellular Imaging & Structural Biology



Key Contact

For further information about this research, please contact the research group leader.

Department / Centre

Biochemistry and Molecular Biology

Unit / Centre

Ascher laboratory: Structural biology and bioinformatics